Simultaneous integrated boost of intensity ‐modulated radiation therapy to Stage II‐III non‐small cell lung cancer with metastatic lymph nodes

The objective response rate (ORR) was 90%, with CR 25%, PR 65%, NC 10%, and PD 0%. Although radiotherapy toxicity was common, there were no grade ≥3, w ith radiation pneumonitis (10 cases), esophagitis (17 cases), and dermatitis (12 cases). The local control rates at 1, 3, and 5 years were 85%, 75%, and 70%, respectively. The overall survival（OS）and local progression‐free survival (LPFS) rates at 1, 3, and 5 years were 90%, 42.6%, and 35.5% and 84.4%, 35.5%, and 28.4%, respectively. SIB‐IMRT can significantly improve ORR and survival for stage II‐III NSCLC with metastatic lymph nodes, with high safety, and satisfactory efficacy. However, due to the limitation of small sample, these findings are needed to confirm by future trials w ith a larger sample size.

Source: Cancer Medicine - September 8, 2020 Category: Cancer & Oncology Authors: Qing ‐Song Li, Na Liang, Wei‐Wei Ouyang, Sheng‐Fa Su, Zhu Ma, Yi‐Chao Geng, Wen‐Gang Yang, Yin‐Xiang Hu, Hui‐Qin Li, Bing Lu Tags: ORIGINAL RESEARCH Source Type: research